HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the second quarter and half year ended September 30, 2016 under International Financial Reporting Standards (IFRS).
Q2 FY17: Key Highlights
Revenues at Rs. 35.9 billion: QoQ growth: 11%
YoY decline: 10%
Gross Profit Margin at 56.0%. Lower by ~530 bps versus the same quarter last year
Research & Development (R&D) spend at Rs. 5.2 billion. [14.5% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 11.8 billion [YoY increase: 6%]
Includes NPPA provision of Rs. 344 million, explained in details in the note
EBITDA at Rs. 6.4 billion [17.9% of Revenues]
Profit after tax at Rs. 2.9 billion [8.2% of Revenues]
H1 FY17: Key Highlights
Revenues at Rs. 68.2 billion
YoY decline: 12%
Gross Profit Margin at 56.1%. Lower by ~510 bps versus H1 FY16
Research & Development (R&D) spend at Rs. 10.0 billion. [14.7% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 24.1 billion [YoY increase: 9%]
EBITDA at Rs. 10.4 billion [15.2% of Revenues]
Profit after tax at Rs. 4.2 billion [6.2% of Revenues]
Commenting on the results, Co-chairman and CEO, G V Prasad said, “All our major businesses have shown sequential improvement over the previous quarter with revenues growing by 11% and EBITDA by 61%. We have made considerable progress in our remediation efforts and continue to work on addressing the concerns of the regulators. Looking ahead we will continue to focus on launching new products in our generics business, improving productivity and strengthening our quality management systems.”
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.